Since many of our products are used to help children with ADHD enjoy reading, we found this to be important information to share with our readers!
WEDNESDAY, Nov. 12 (HealthDay News) reported-- The U.S. Food and Drug Administration has approved a 30-minute onset of action for Focalin XR to treat attention-deficit hyperactivity disorder (ADHD).
They reported that the early onset could especially benefit children ages 6 to 12 during the morning as they get ready for school, the company said in a news release. The drug helps curtail symptoms for up to 12 hours.
ADHD affects about 3 percent to 6 percent of children in the United States, with symptoms including inattention, hyperactivity, and impulsive behavior, Novartis said.
The new labeling is based on clinical data, including a study of 86 children ages 6 to 12. The drug provided significant symptom improvement 30 minutes after administration, compared to a non-medicinal placebo, the company said.